These adverse symptoms are observed to occur in more than half of NSCLC patients with EGFR mutation(s).26, 27 A meta-analysis reported gefitinib was associated with lower treatment-related diarrhea and skin rash.26 Lower treatment-related toxicities could substantially improve QOL, which was consistent with our finding in this study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.